NCT00062075View on ClinicalTrials.gov

Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

March 31, 2007

Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Promyelocytic Leukemia (M3)Recurrent Adult Acute Myeloid Leukemia
Interventions
DRUG

romidepsin

Given IV

Trial Locations (2)

37232

Vanderbilt University, Nashville

60637-1470

University of Chicago Comprehensive Cancer Center, Chicago

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00062075 - Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter